These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 15526240

  • 1. Reassessing guidelines for heart failure.
    Drexler H, Wollert KC.
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S28-33. PubMed ID: 15526240
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 3. Conclusions on the management of heart failure.
    Swedberg K.
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S34-6. PubMed ID: 15526241
    [Abstract] [Full Text] [Related]

  • 4. Pharmacologic therapies across the continuum of left ventricular dysfunction.
    Abraham WT, Greenberg BH, Yancy CW.
    Am J Cardiol; 2008 Sep 08; 102(5A):21G-28G. PubMed ID: 18722188
    [Abstract] [Full Text] [Related]

  • 5. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan 08; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 6. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
    Fabbri G, Gorini M, Maggioni AP, Di Lenarda A, Area Scompenso ANMCO, Firenze.
    G Ital Cardiol (Rome); 2007 Feb 08; 8(2):102-6. PubMed ID: 17402354
    [Abstract] [Full Text] [Related]

  • 7. Cellular basis for therapeutic choices in heart failure.
    Opie LH.
    Circulation; 2004 Oct 26; 110(17):2559-61. PubMed ID: 15505109
    [No Abstract] [Full Text] [Related]

  • 8. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy.
    Jneid H, Moukarbel GV, Dawson B, Hajjar RJ, Francis GS.
    Am J Med; 2007 Dec 26; 120(12):1090.e1-8. PubMed ID: 18060931
    [Abstract] [Full Text] [Related]

  • 9. The HF epidemic: the need for new treatment strategies.
    Carson PE.
    J Renin Angiotensin Aldosterone Syst; 2000 Jun 26; 1(2 Suppl):S32-4. PubMed ID: 17199218
    [Abstract] [Full Text] [Related]

  • 10. [Pharmacological therapy of chronic heart failure in the elderly].
    Sabbadini G, Di Lenarda A, Metra M, Nodari S, Moretti M, Brentana L, Dei Cas L, Sinagra G.
    Ital Heart J; 2004 Dec 26; 5 Suppl 10():37S-51S. PubMed ID: 15712511
    [Abstract] [Full Text] [Related]

  • 11. Angiotensin II receptor blockers in chronic heart failure--not as ELITE as expected!
    Farquharson CA, Struthers AD.
    J Renin Angiotensin Aldosterone Syst; 2000 Mar 26; 1(1):21-2. PubMed ID: 11967790
    [Abstract] [Full Text] [Related]

  • 12. Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure.
    Shah NC, Pringle S, Struthers A.
    J Renin Angiotensin Aldosterone Syst; 2006 Mar 26; 7(1):20-30. PubMed ID: 17083070
    [Abstract] [Full Text] [Related]

  • 13. Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade.
    Pitt B, Fonarow GC, Gheorghiade M, Deedwania PC, Duprez DA.
    Am J Cardiol; 2006 May 22; 97(10A):26F-33F. PubMed ID: 16698332
    [Abstract] [Full Text] [Related]

  • 14. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
    Kubota T, Takeshita A.
    Nihon Rinsho; 2003 May 22; 61(5):801-6. PubMed ID: 12755006
    [Abstract] [Full Text] [Related]

  • 15. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
    Volpe M, Tocci G, Sciarretta S, Verdecchia P, Trimarco B, Mancia G.
    J Hypertens; 2009 May 22; 27(5):941-6. PubMed ID: 19381108
    [Abstract] [Full Text] [Related]

  • 16. Aldosterone blockade in heart failure.
    Struthers AD.
    J Renin Angiotensin Aldosterone Syst; 2004 Sep 22; 5 Suppl 1():S23-7. PubMed ID: 15526239
    [Abstract] [Full Text] [Related]

  • 17. Use of valsartan in post-myocardial infarction and heart failure patients.
    Liu PP, Maggioni A, Velazquez EJ.
    J Renin Angiotensin Aldosterone Syst; 2006 Jun 22; 7 Suppl 1():S19-22. PubMed ID: 16986231
    [Abstract] [Full Text] [Related]

  • 18. How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?
    Gustafsson F, Segura J, Ruilope LM.
    J Hypertens; 2010 Aug 22; 28(8):1595-8. PubMed ID: 20613629
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG.
    J Indian Med Assoc; 2009 Mar 22; 107(3):178-82. PubMed ID: 19810392
    [Abstract] [Full Text] [Related]

  • 20. beta-Blocker therapy in heart failure.
    Doughty RN.
    Heart Fail Monit; 2000 Mar 22; 1(1):2-7. PubMed ID: 12634875
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.